Dr Sarah Wordsworth
BSc MSc PhD
Associate Professor and University Research Lecturer
Sarah Wordsworth joined the Health Economics Research Centre in January 2003 and has developed a research programme within HERC on the economics of genetic and genomic technologies. Of particular interest are the economics of translating genomic high-throughput technologies from research into clinical practice, in both cancer and cardiovascular disease. In October 2006, Sarah took up a post-doctoral fellowship from the National Institute for Health Research. This fellowship involved methodological and applied research on the economic evaluation of novel genomic technologies in the NHS. Sarah's other interests include costing methodology and trial based evaluations in the areas of eye disease, blood transfusion, cardiac surgery and surgery for obesity. Prior to this appointment, Sarah worked in the Health Economics Research Unit at the University of Aberdeen from 1995-2002, after completing her MSc in Health Economics in 1995 at the University of York.
Evaluating the Outcomes Associated with Genomic Sequencing: A Roadmap for Future Research
BUCHANAN JR. and WORDSWORTH S., (2018), PharmacoEconomics - Open
Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study.
Doble B. et al, (2018), Health Qual Life Outcomes, 16
Effect of a strategy of supraglottic airway device versus tracheal intubation during out-of-hospital cardiac arrest on functional outcome: the AIRWAYS-2 randomized clinical trial.
Benger J. et al, (2018), JAMA - Journal of the American Medical Association, 320, 779 - 791
Valuation of Health and Nonhealth Outcomes from Next-Generation Sequencing: Approaches, Challenges, and Solutions
Regier DA. et al, (2018), Value in Health
Using “Big Data” in the Cost-Effectiveness Analysis of Next-Generation Sequencing Technologies: Challenges and Potential Solutions
Wordsworth S. et al, (2018), Value in Health